Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistRefills Health was cited for misbranding compounded semaglutide products in violation of the Federal Food, Drug, and Cosmetic Act. The company falsely represented itself as the compounder of these drugs on its website despite not actually manufacturing them, and made unsubstantiated claims that the products were "clinically proven" and equivalent to FDA-approved treatments, implying FDA approval when none existed. These false or misleading statements regarding labeling and advertising rendered the compounded drug products misbranded under sections 502(a) and 502(bb) of the FDCA.